Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 Years of follow-up of the GHSG HD9 study

Journal of Clinical Oncology

Volumn 27, Issue 27, 2009, Pages 4548-4554

  Engert, Andreas ^a   Diehl, Volker ^b   Franklin, Jeremy ^b   Lohri, Andreas ^b   Dörken, Bernd ^b   Ludwig, Wolf Dieter ^b   Koch, Peter ^b   Hänel, Mathias ^b   Pfreundschuh, Michael ^b   Wilhelm, Martin ^b   Trümper, Lorenz ^b   Aulitzky, Walter Erich ^b   Bentz, Martin ^b   Rummel, Mathias ^b   Sezer, Orhan ^b   Müller Hermelink, Hans Konrad ^b   Hasenclever, Dirk ^b   Löffler, Markus ^b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SECOND CANCER; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; PREDNISONE; PROCARBAZINE; TREATMENT OUTCOME; VINBLASTINE; VINCRISTINE;

EID: 71049118685     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.8820     Document Type: Article

References (31)

1. Diehl V, Mauch P, Harris NL: Hodgkin's Disease, in De Vita V (ed): Cancer Principles and Practice of Oncology. Philadelphia, PA, Lippincott Williams & Wilkins, 2001, pp 2339-2387
2. Canellos GP, Anderson JR, Propert KJ, et al: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1484, 1992
3. Bonadonna G, Zucali R, Monfardini S, et al: Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 336:252-259, 1975
4. Connors JM, Klimo P, Adams G, et al: Treatment of advanced Hodgkin's disease with chemotherapy - comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: A report from the National Cancer Institute of Canada clinical trials group. J Clin Oncol 15:1638-1645, 1997
5. Viviani S, Bonadonna G, Santoro A, et al: Alternating versus hybrid and ABVD combinations in advanced Hodgkin's disease: Ten-year results. J Clin Oncol 114:1421-1430, 1996
6. Glick JH, Young ML, Harrington D, et al: MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: The 8-year results of the intergroup trial. J Clin Oncol 16:19-26, 1998
7. Horning S, Chao N, Negrin R, et al: High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices. Blood 89:801-813. 1997
8. Josting A, Franklin J, May M, et al: New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 20:221-230, 2002
9. Tesch H, Diehl V, Lathan B, et al: Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone schema and adjuvant radiotherapy: A study of the German Hodgkin Study Group. Blood 92:4560-4567, 1998
10. Diehl V, Franklin J, Hasenclever D, et al: BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: Interim report from a trial of the German Hodgkin Study Group. J Clin Oncol 16:3810-3821, 1998
11. Diehl V, Franklin J, Pfreundschuh M, et al: Standard and increased-dose BEACOPP chemotherapy compared with COPP/ABVD for advanced Hodgkin's disease. N Engl J Med 348:2386-2395, 2003
12. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin's disease. N Engl J Med 339: 1506-1514, 1998
13. Horning SJ: Risk, Cure and Complications in Advanced Hodgkin Disease. Hematology ASH Education Program Book 197-203, 2007
14. Canellos GP, Gollub J, Neuberg D, et al: Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up. Ann Oncol 14:268-272, 2003
15. Klimo P, Connors JM: MOPP/ABV hybrid program: Combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. J Clin Oncol 3:1174-1182, 1985
16. Canellos GP, Niedzwiecki D: Long-term follow-up of Hodgkin's disease trial. N Engl J Med 346:1417-1418, 2002
17. Duggan D, Petroni G, Johnson J, et al: A randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial. J Clin Oncol 21:607-614, 2003
18. Hirsch A, Vander Els N, Straus DJ, et al: Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease. J Clin Oncol 14:1297-1305, 1996
19. Hull MC, Morris CG, Peine CJ, et al: Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA 290:2831-2837, 2003
20. Chapman RM, Sutcliffe SB, Malpas JS, et al: Male gonadal dysfunction in Hodgkin's disease: A prospective study. JAMA 245:1323-1328, 1981
21. Behringer K, Breuer K, Reineke T, et al: Secondary amenorrhoea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: A report from the German Hodgkin Lymphoma Study Group (GHSG). J Clin Oncol 23:7555-7564, 2005
22. Sieniawski M, Reineke T, Nogova L, et al: Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: A report of the German Hodgkin Study Group (GHSG). Blood 111: 71-76, 2008
23. Sieniawski M, Reineke R, Josting A, et al: Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Ann Oncol 19:1795-1801, 2008
24. Van der Kaaij M, Heutte N, Le Stang N, et al: Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Ètude des Lymphomes de l'Adulte. J Clin Oncol 25:2825-2832, 2007
25. Kulkami SS, Sasty PS, Saikia TK, et al: Gonadal function following ABVD therapy for Hodgkin's disease. Am J Clin Oncol 20:354-357, 1997
26. Viviani S, Santoro A, et al: Gonadal toxicity after combination chemotherapy for Hodgkin's disease: Comparative results of MOPP vs. ABVD. Eur J Cancer Clin Oncol 21:601-605, 1985
27. Da Cunha MF, Meistrich ML, Fuller LM, et al: Recovery of spermatogenesis after treatment for Hodgkin's disease: Limiting dose of MOPP chemotherapy. J Clin Oncol 2:571-577, 1984
28. Bramswig JH, Heimes U, Heiermann E, et al: The effects of different cumulative doses of chemotherapy on testicular function: Results in 75 patients treated for Hodgkin's disease during childhood or adolescence. Cancer 65:1298-1302, 1990
29. Petti N, Anghel G, Schimberni M, et al: Successful paternity with microassisted fertilization after total body irradiation-based conditioning for autologous bone marrow transplantation. Hematol J 4:285-288, 2003
30. Engert A, Franklin J, Mueller RP, et al: HD12 randomized trial comparing 8 dose-escalated cycles of BEACOPP with 4 escalated and 4 baseline cycles in patients with advanced stage Hodgkin lymphoma (HL): An analysis of the German Hodgkin Lymphoma Study Group (GHSG), University of Cologne. Blood 108:33a, 2006 (abstr 99)
31. Kobe C, Dietlein M, Franklin J, et al: Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 112: 3989-3994, 2008